可选产品分析
经您允许,我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Cognizant Technology Solutions Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $27.5B | |
|---|---|---|
| Revenue (ttm) | 21.6B | |
| Net income (ttm) | 2.2B | |
| EPS (ttm) | $4.64 | |
| Shares out | 450.4M | |
| P/E (trailing) | 14.3x | |
| P/E (forward) | 9.4x | |
| Dividend | $1.32 (2.00%) | |
| Volume | 5,107,961 | |
| Beta | 0.85 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $18.51B | $19.43B | $19.35B | $19.74B | $21.11B | +3.3% |
| Gross profit | $6.90B | $6.98B | $6.69B | $6.78B | $7.12B | +0.8% |
| Operating income | $2.83B | $2.97B | $2.69B | $2.89B | $3.39B | +4.6% |
| Net income | $2.14B | $2.29B | $2.13B | $2.24B | $2.23B | +1.1% |
| EPS (diluted) | $4.05 | $4.41 | $4.21 | $4.51 | $4.56 | +3.0% |
| EBITDA | $3.41B | $3.60B | $3.38B | $3.53B | $4.17B | +5.2% |
| R&D | — | — | — | — | — | — |
| SG&A | $3.50B | $3.44B | $3.25B | $3.22B | $3.24B | -1.9% |
Recent company headlines from major financial publishers.
The base case represents the modal expected trajectory, reflecting steady execution across multi-year enterprise contracts, mid-single-digit top-line growth, and modest margin expansion driven by delivery automation. Regulated domain stability in Health Sciences and Financial Services sustains double-digit operating margins and robust cash generation, while ongoing share repurchases support diluted earnings compounding. This path establishes Fair value at $94.37 with an assigned probability of 60.0%, representing 62.2% upside from $58.17.
In the bull case, enterprise digital transformation spending re-accelerates as large corporate clients aggressively deploy generative AI workflows and modern cloud architecture. Health Sciences and Financial Services expand above historical mid-single-digit rates, and European market share gains accelerate across the United Kingdom and Continental Europe. Operational leverage and delivery automation expand operating margins, while disciplined free cash flow conversion accelerates share count retirement. This trajectory targets $116.80 with an assigned probability of 20.0%, offering an implied return of 100.8% from $58.17.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.0% | $103 | $105 | $109 | $112 | $116 |
| 8.5% | $96.0 | $98.3 | $101 | $104 | $107 |
| 9.0% | $90.2 | $92.2 | $94.4 | $96.7 | $99.2 |
| 9.5% | $85.3 | $87.0 | $88.8 | $90.7 | $92.8 |
| 10.0% | $80.9 | $82.4 | $83.9 | $85.5 | $87.3 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值,并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |